PRINCETON, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Ann Behringer, director of human resources at Novo Nordisk, has been named "Human Resource Person of the Year" by the Society for Human Resource Management during a recent awards ceremony at its Princeton chapter. Selected from human resources specialists throughout the state, Behringer was recognized for her outstanding leadership, vision, and other professional and personal qualities.
(Photo: http://www.newscom.com/cgi-bin/prnh/20041026/PHTU028 )
(Logo: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO )
Jeff Frazier, vice president of human resources, said, "Ann's award comes as no surprise to her colleagues here at Novo Nordisk, both in the United States and internationally. She is a wonderful asset to our organization, helping many Novo Nordisk employees and business units achieve various developmental and professional milestones. Ann has made significant contributions to our organization, and we are proud she is being honored by the Society for Human Resource Management."
Since joining Novo Nordisk in 1997, Behringer has received several internal awards and career advancements for accomplishments in her field. A certified senior professional in human resources management, Behringer also is certified in the Myers-Briggs type indicator and Hogan personality-based assessment tools. She is a member of the Society for Human Resource Management and the American Society of Training and Development. Behringer received an IRIS award of merit from the New Jersey chapter of the International Association of Business Communicators for her work on an innovative Novo Nordisk employee handbook.
In addition to leadership and vision, criteria for the "Human Resource Person of the Year" award include code of ethics, change, innovation, and influence. Candidates are selected from among human resources professionals throughout New Jersey.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 19,600 full-time employees in 69 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol "NVO." For global information, visit http://www.novonordisk.com/; for United States information, visit http://www.novonordisk-us.com/.
AP PhotoExpress Network: PRN8 PRN Photo Desk, email@example.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20041026/PHTU028
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020404/NVOLOGO
PRN Photo Desk, firstname.lastname@example.orgNovo Nordisk